X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (523) 523
life sciences & biomedicine (445) 445
humans (443) 443
aptamers, nucleotide - therapeutic use (198) 198
animals (170) 170
aptamers (168) 168
vascular endothelial growth factor a - antagonists & inhibitors (158) 158
aptamer (136) 136
ophthalmology (130) 130
aptamers, nucleotide - administration & dosage (122) 122
female (120) 120
aptamers, nucleotide - adverse effects (118) 118
male (116) 116
ranibizumab (116) 116
bevacizumab (104) 104
pharmacology & pharmacy (103) 103
aptamers, nucleotide - chemistry (95) 95
macular degeneration - drug therapy (93) 93
deoxyribonucleic acid--dna (87) 87
aged (84) 84
biochemistry & molecular biology (80) 80
chemistry (79) 79
cancer (76) 76
antibodies, monoclonal, humanized (73) 73
treatment outcome (73) 73
vascular endothelial growth factor (70) 70
physical sciences (69) 69
aptamers, nucleotide - pharmacology (67) 67
ligands (67) 67
middle aged (67) 67
drug delivery systems (65) 65
macular degeneration (63) 63
proteins (63) 63
angiogenesis inhibitors - therapeutic use (62) 62
intravitreal injections (62) 62
research (60) 60
review (60) 60
medicine, research & experimental (58) 58
research & experimental medicine (58) 58
angiogenesis inhibitors - adverse effects (57) 57
nanoparticles (56) 56
pegaptanib (56) 56
science & technology - other topics (56) 56
aptamers, nucleotide - metabolism (52) 52
physiological aspects (52) 52
ribonucleic acid--rna (52) 52
mice (51) 51
aged, 80 and over (50) 50
choroidal neovascularization - drug therapy (47) 47
antibodies, monoclonal - therapeutic use (46) 46
care and treatment (46) 46
analysis (45) 45
angiogenesis inhibitors - administration & dosage (45) 45
cell line, tumor (45) 45
health aspects (45) 45
drugs (44) 44
rna (43) 43
vitreous body (43) 43
biotechnology & applied microbiology (42) 42
gene expression (42) 42
oligonucleotides (42) 42
selex aptamer technique (42) 42
medicine (41) 41
visual acuity (41) 41
drug delivery (40) 40
injections (40) 40
macular edema - drug therapy (40) 40
chemistry, multidisciplinary (38) 38
cancer therapies (37) 37
clinical trials (37) 37
drug therapy (37) 37
selex (37) 37
abridged index medicus (36) 36
fluorescein angiography (36) 36
retrospective studies (36) 36
dna (35) 35
tumors (35) 35
antibodies, monoclonal - adverse effects (34) 34
aptamers, nucleotide (34) 34
base sequence (33) 33
hematology (33) 33
tomography, optical coherence (33) 33
age-related macular degeneration (32) 32
chemotherapy (32) 32
diabetic retinopathy - drug therapy (32) 32
multidisciplinary sciences (32) 32
studies (32) 32
chemistry, medicinal (31) 31
oncology (31) 31
science (31) 31
usage (31) 31
antibodies, monoclonal, humanized - therapeutic use (30) 30
aptamers, nucleotide - genetics (30) 30
diabetic retinopathy (30) 30
pharmacology (30) 30
risk factors (29) 29
adult (28) 28
biology (28) 28
clinical trials as topic (28) 28
nucleic acids (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (623) 623
German (12) 12
Japanese (5) 5
French (4) 4
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Korean (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nanomedicine, ISSN 1549-9634, 04/2015, Volume 11, Issue 3, pp. 671 - 679
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2016, Volume 169, pp. 68 - 72
Abstract Purpose To investigate a certain set of methodological limitations in published anti-VEGF randomized controlled trials (RCT). Design Descriptive... 
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Aptamers, Nucleotide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - etiology | Male | Treatment Outcome | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Randomized Controlled Trials as Topic | Ranibizumab - adverse effects | Angiogenesis Inhibitors - therapeutic use | Female | Angiogenesis Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions - diagnosis | Databases, Factual | Physiological aspects | Medical colleges | Vascular endothelial growth factor | Analysis | Eye diseases | Endothelial growth factors | Cataracts | Diabetic retinopathy | Internal medicine | Funding | Clinical trials | Impact factors | Studies | Macular degeneration | Medicine | Reading | Archives & records | Surgery | Journals | Diabetes | Drug dosages | Evidence-based medicine | Research methodology | Age | Index Medicus | Abridged Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Nature biotechnology, ISSN 1546-1696, 06/2018, Volume 36, Issue 7, pp. 606 - 613
Journal Article